Physician profile
Gail E Kirby
NPI 1760460869
$17,980.06
in general payments reported to CMS, 2019-2025
27 companies · $1,904 in 2025
The $1,904 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $913 · 2022: $1,279 · 2023: $7,382 · 2024: $6,503 · 2025: $1,904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,339 · Consulting Fee: $4,875 · Travel and Lodging: $2,613 · Honoraria: $2,300 · Education: $661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,338.94 |
| Consulting Fee | $4,875.00 |
| Travel and Lodging | $2,613.21 |
| Honoraria | $2,300.00 |
| Education | $660.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $4,933.74 | 2023-2025 | |
| Horizon Therapeutics Plc | $3,905.16 | 2021-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $3,423.49 | 2021-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $766.17 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $637.94 | 2021-2024 | Rayaldee |
| Amgen INC. | $588.95 | 2021-2025 | Krystexxa, Tavneos |
| Akebia Therapeutics INC | $585.70 | 2021-2025 | Vafseo, Auryxia |
| Travere Therapeutics, INC. | $524.23 | 2022-2025 | Filspari |
| Calliditas Therapeutics US INC. | $483.47 | 2022-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $348.52 | 2021-2025 | Jynarque |
| Novo Nordisk INC | $256.71 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Ardelyx, INC. | $234.53 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Mallinckrodt Hospital Products INC. | $205.82 | 2023-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.59 | 2023-2025 | Jardiance |
| Vifor Pharma, INC. | $203.15 | 2021-2025 | Veltassa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $174.94 | 2021-2024 | Benlysta, Arexvy |
| Lilly USA, LLC | $165.83 | 2023-2025 | Jardiance |
| Nxstage Medical, INC. | $80.29 | 2024 | |
| Fresenius USA Marketing, INC. | $69.23 | 2021-2023 | Velphoro |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $36.78 | 2023-2025 | |
| Daiichi Sankyo INC. | $34.95 | 2021-2024 | Injectafer |
| Aurinia Pharma U.S., INC. | $25.03 | 2023 | Lupkynis |
| Kyowa Kirin, INC. | $23.35 | 2025 | |
| Alexion Pharmaceuticals, INC. | $21.63 | 2025 | Ultomiris |
| Genentech USA, INC. | $20.21 | 2025 | Gazyva |
| Ultragenyx Pharmaceutical INC. | $16.03 | 2023 | |
| Athena Bioscience, LLC | $8.62 | 2024 | Nexiclon Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gail Kirby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.